Press Room

Event

RDD Europe 2019

Start
Tuesday, May 07, 2019 - 09:00
End
Friday, May 10, 2019 - 17:00
Location: Lisbon, Portugal
Booth Number: Table nr. 64

RDD Europe 2019 will be held at the Estoril Congress Center in Portugal and Hovione will be present.

 

Hovione, together with Hovione Technology will present an interactive workshop session:
 

Fully Integrated Dry Powder Solutions

  • Wednesday, May 8th | 2:00pm, 3:15pm and 4:30pm – Room F7
  • Presented by: Beatriz Fernandes, M.Sc., Eunice Costa, Ph.D., João Ventura, Ph.D.and Maria Braga, Ph.D.

This session will review traditional and advanced formulation approaches for inhalation and nasal delivery, coupling key aspects across particle engineering as well as formulation and device design. Case studies will be presented focused on the interaction between traditional carrier-based formulation components and the final outcome in terms of aerodynamic performance, manufacturability and expected lung dose. Further case studies will look at carrier-free formulations for DPIs and for nasal applications, advanced particle engineering technologies applicable to labile biomolecules and finally design optimization of a cost-effective capsule-based inhaler and device development targeting high dose delivery.
 
Hovione will also have two Communications:
 
May 9, 2019 | 11:00 am

  • Spray Drying of Inhalable Biopharmaceuticals of Increasing Size and 3D Structure Complexity: From 30 to 250 kDa (Session 4: Poster in the podium)
    Diana Fernandes, M.Sc., Hovione, Loures, Portugal

 
May 10, 2019 |11:15 am

  • Continuous Processing: Challenging the Current Manufacturing Paradigm for Dry Powder Inhalers (Session 7: New Approaches to Inhalation Product Development and Production)
    Eunice Costa, Ph.D., Hovione, Loures, Portugal

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping
News Medical Life Sciences, 1 June 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026

Every year, the largest bank in Portugal, Caixa Geral de Depósitos recognizes some of Portugal’s brightest young minds through the Caixa +Mundo Awards, providing nearly €800,000 in scholarships to students as they pursue higher education. In this year´s edition, Caixa named the award bestowed upon students pursuing science for Diane Villax. This prestigious honor places Diane Villax among the award’s namesakes – a distinguished group of prominent personalities who have made notable contributions to Portugal´s socio-economic, cultural, political and scientific development over the last 50 years, such as António Ramalho Eanes, Mário Soares, José Saramago, Sophia de Mello Breyner, Leonor Beleza, Elvira Fortunato, Rui Nabeiro, Américo Amorim, and José Manuel de Mello. Diane Villax will also honor the seven scientific award winners by personally meeting with each of them, and following their journeys as future innovators and leaders. But this honor is about far more than one individual. It is a celebration of an entire organization and the people behind it. For 67 years, generations of dedicated teams have worked together with passion, purpose, and excellence to manufacture life-saving medicines and advance science that has a real impact on people. This recognition belongs to all of us.    

News

Prestigious Caixa +Mundo Award named in honor of Diane Villax

May 14, 2026

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device. Read the full article at OINDPnews.com      

Press Clipping
OINDP - Orally inhaled and nasal drug products news, May 11, 2026

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

May 11, 2026

Also in Events

See All